Digoxin

Hypercalcemia increases risk of digoxin toxicity; synergistic arrhythmias may occur. Avoid concurrent administration; if necessary, administer slowly with ECG monitoring.

Coadministration not recommended due to risk of serious toxicities from increased digoxin plasma concentration.

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium.

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Coadministration increases plasma concentrations of digoxin, a P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities.

Rarely associated with ventricular fibrillation when combined with adenosine injection. Use with caution due to potential additive depressant effects on SA and AV nodes.

Concomitant use increases risk of digoxin toxicity.

Increases digoxin serum concentration by 70%. Requires monitoring and dose reduction of 30-50%.

Potentiates electrophysiologic and hemodynamic effects resulting in bradycardia, sinus arrest, and AV block. Also increases digoxin concentration.

Particularly if administered rapidly by IV route, may produce serious arrhythmias in digitalized patients.

Avoid concomitant use; synergistic arrhythmias may occur. Calcium chloride may cause hypercalcemia, increasing risk of digoxin toxicity. Monitor ECG closely if use unavoidable.

Synergistic arrhythmias may occur. Calcium chloride may cause hypercalcemia, increasing digoxin toxicity risk. Close ECG monitoring required if concomitant use unavoidable.

Increases digoxin serum concentration by 58% and AUC by 39%. Requires monitoring and dose adjustment.

CAROSPIR increases apparent exposure to digoxin. Reduce digoxin dose by 15-30% and monitor serum digoxin concentrations.

Both drugs slow atrioventricular conduction and decrease heart rate, increasing risk of bradycardia; digoxin concentrations may increase.

Can increase serum concentration and prolong half-life of digoxin. Monitor serum digoxin levels.

Elevated digoxin serum concentrations reported with concomitant clarithromycin use, including cases of digoxin toxicity with potentially fatal arrhythmias.

P-gp substrate; rhabdomyolysis has been reported with coadministration of colchicine.

P-glycoprotein substrate with reported rhabdomyolysis when coadministered with colchicine.

Colestipol may reduce availability of digoxin with conflicting study results. Particular caution required; discontinuing colestipol could be hazardous if digoxin was titrated during colestipol use.

Digoxin causes bradycardia and should be avoided with crizotinib, which can also cause bradycardia.

Concomitant use with digoxin associated with higher rate of torsades de pointes. Use with caution.

Increases digoxin AUC by 150%. Requires monitoring and dose reduction of 30-50%.

Epoprostenol decreases digoxin oral clearance by 15%, leading to elevated digoxin concentrations that may be clinically significant in patients prone to digoxin toxicity.

Concomitant administration with erythromycin results in elevated digoxin serum levels.

Coadministration has been reported to result in elevated digoxin serum levels.

Concomitant use increases digoxin blood levels by 10-20% at some time points. Both drugs slow atrioventricular conduction and decrease heart rate, increasing bradycardia risk.

Etodolac may cause elevated serum levels and increased toxicity of digoxin through effects on renal prostaglandins.

P-glycoprotein inhibitor that may decrease efflux of everolimus from intestinal cells and increase everolimus blood concentrations.

P-glycoprotein inhibitor may decrease everolimus efflux from intestinal cells and increase everolimus blood concentrations.

Drug that slows heart rate/AV conduction. Concomitant use during fingolimod initiation may result in severe bradycardia or heart block.

Drug that slows heart rate and AV conduction. Experience is limited; concomitant use during initiation may cause severe bradycardia or heart block.

Increases digoxin serum concentration by 129-212%. Requires monitoring and dose reduction of 30-50%.

Slow dissolution digoxin tablets may have increased serum levels and enhanced action with glycopyrrolate. Monitor for increased action or consider alternative dosage forms.

Slow dissolution digoxin tablets may have increased serum levels and enhanced action when coadministered with glycopyrrolate. Monitor for increased action; consider alternative dosage forms.

Indomethacin may prolong digoxin half-life, increasing risk of digoxin toxicity. Close monitoring with frequent ECGs and serum digoxin levels required in neonates.

Increases digoxin serum concentration by 80%. Requires monitoring and dose reduction of 30-50%.

Lapatinib increases oral digoxin AUC approximately 2.8-fold. Monitor serum digoxin concentrations and reduce digoxin dose by half if concentration exceeds 1.2 ng/mL.

Electrolyte imbalances caused by mannitol may result in cardiac adverse reactions in patients receiving digoxin. Monitor serum electrolytes and discontinue if cardiac status worsens.

Mirabegron increases digoxin Cmax by 29% and AUC by 27%. Use lowest digoxin dose and monitor serum concentrations for dose titration.

Reported to increase PR interval and QRS duration. Reports of first degree atrioventricular block or bundle branch block with digitalis.

Amiodarone increases serum digoxin concentration, requiring dose reduction by half or discontinuation and monitoring for toxicity.

Increases digoxin serum concentration by 57% and AUC by 15%. Requires dose reduction of 30-50% and monitoring.

PALOPEGTERIPARATIDE increases serum calcium, which may predispose patients to digitalis toxicity if hypercalcemia develops. Digoxin efficacy may be reduced if hypocalcemia is present. Serum calcium and digoxin levels should be monitored.

Concomitant use can increase serum concentration and prolong half-life of digoxin. Monitor serum digoxin levels.

Drug that may decrease heart rate; should generally not be initiated with PONVORY due to additive effects.

Major contributing factor to digitalis toxicity.

Increases digoxin AUC by 60-270%. Requires monitoring and dose reduction of 30-50%.

Propafenone may increase digoxin levels, requiring monitoring.

Digoxin serum concentrations increased 54-83%. Reduce digoxin dose by 30-50% and monitor serum concentrations.

Quinidine slows digoxin elimination and reduces volume of distribution, potentially doubling serum digoxin levels; digoxin dose reduction usually needed.

Quinidine slows elimination of digoxin and reduces its volume of distribution, potentially doubling serum digoxin levels; digoxin dose reduction usually needed.

Quinine inhibits CYP3A4 and increases digoxin plasma concentration, potentially leading to toxicity.

Increases digoxin serum concentration by 50%. Requires monitoring and dose reduction of 30-50%.

Remibrutinib increases P-gp substrate exposure. Monitor frequently for adverse reactions with substrates where minimal concentration changes may cause serious effects.

Digoxin AUC increased 86%. Monitor serum digoxin concentrations and consider dose reduction.

Drug that may decrease heart rate; treatment with siponimod should generally not be initiated due to additive heart rate effects.

Calcium administration may increase digoxin effects and lead to toxicity including serious or fatal cardiac arrhythmias. Consider reducing volume or rate of administration.

Consider reducing the volume or rate of administration due to increased risk of digoxin toxicity with calcium-containing solutions.

Proarrhythmic events more common with concurrent use. Increased risk of arrhythmias with concomitant administration.

Digitalis glycoside; concomitant use increases risk of bradycardia and hypotension.

Spironolactone increases half-life of digoxin, resulting in increased serum levels and potential digitalis toxicity.

Spironolactone increases digoxin half-life, leading to increased serum levels and potential digitalis toxicity; electrolyte disturbances increase toxicity risk.

May cause sudden extrusion of potassium from muscle cells and arrhythmias in digitalized patients.

Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored.

Concomitant use can increase serum concentration and prolong half-life of digoxin. Monitor serum digoxin levels.

Increases digoxin serum concentration by 50% and AUC by 85%. Requires monitoring and dose reduction.

Co-administration increases digoxin peak plasma concentration (49%) and trough concentration (20%). Monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan.

Telmisartan co-administration increases digoxin peak plasma concentration (49%) and trough concentration (20%). Monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan.

Telmisartan increases digoxin peak plasma concentration by 49% and trough concentration by 20%. Monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan.

Telmisartan co-administration increases digoxin peak plasma concentration (49%) and trough concentration (20%), requiring therapeutic monitoring.

Teriparatide may transiently increase serum calcium, which can predispose patients to digitalis toxicity. Monitor for signs and symptoms of digitalis toxicity.

Increases digoxin serum concentration by 100%. Requires monitoring and dose reduction of 30-50%.

Verapamil increases serum digoxin levels by 50-75% in first week, risking digoxin toxicity. Maintenance doses must be reduced and patient carefully monitored.

P-glycoprotein substrate with narrow therapeutic index. Vemurafenib increased digoxin systemic exposure by 1.8-fold. Avoid concurrent use or consider dose reduction.

Increases digoxin serum concentration by 50-75%. Requires monitoring and dose reduction of 30-50%.

Verapamil increases serum digoxin levels by 50-75% in first week, risking digitalis toxicity. Dose reduction and careful monitoring required.

Acarbose changes the bioavailability of digoxin when coadministered, which may require digoxin dose adjustment.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

May decrease serum digoxin levels (16-22% reduction demonstrated). Monitor digoxin levels carefully during concomitant use.

Albuterol may decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use.

May increase digoxin plasma levels; monitor patients appropriately.

May impair digoxin excretion by declining GFR or tubular secretion. Monitor renal function and digoxin levels.

Decrease digoxin concentrations. Requires monitoring and dose adjustment.

May increase digoxin plasma levels; monitor patients appropriately.

Increases digoxin serum concentration by 22% and AUC by 15%. Requires monitoring and dose adjustment.

May increase digoxin plasma levels; monitor patients appropriately.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Bupropion may decrease plasma digoxin levels. Monitor digoxin levels.

Although may be useful in combination with digoxin, additive effects on AV node conduction can result in advanced or complete heart block.

Canagliflozin increases digoxin exposure. Monitor patients for need to adjust digoxin dosage.

Increases in exposure may be observed when concomitantly used with EPIDIOLEX. Consider therapeutic drug monitoring and dosage reduction.

May be falsely detected as digoxin in standard radioimmunoassays, causing falsely elevated digoxin levels up to 0.5 ng/mL.

Digoxin concentrations increase by about 15% when given with carvedilol; both agents slow AV conduction and decrease heart rate, increasing bradycardia risk.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Increases digoxin serum concentration by 33% and AUC by 43%. Requires monitoring and dose adjustment.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Potential for increased exposure of digoxin. Monitor digoxin concentrations; dose adjustment may be needed to maintain therapeutic levels.

Increased digoxin substrate plasma concentration may occur.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Concomitant use can increase serum concentration and prolong half-life of digoxin. Monitor serum digoxin levels.

Can increase serum digoxin concentration and prolong half-life. Monitor serum digoxin levels.

Monitor serum digoxin levels during concomitant use.

Concomitant use can increase serum concentration and prolong half-life of digoxin. Monitor serum digoxin levels.

Concomitant use may increase serum concentration and prolong half-life of digoxin.

Anticholinergic agents may affect gastrointestinal absorption of slowly dissolving digoxin formulations, potentially increasing serum digoxin concentration.

Increases digoxin serum concentration by 20%. Requires monitoring and dose adjustment.

Potential additive effects on cardiac conduction when administered with diltiazem. Careful monitoring recommended.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Elagolix increases digoxin plasma concentrations. Monitor digoxin concentrations and signs of toxicity when initiating or discontinuing elagolix.

ORIAHNN may increase digoxin plasma concentrations. Increase monitoring of digoxin concentrations and signs of toxicity when initiating or discontinuing ORIAHNN.

Eliglustat may increase digoxin concentrations as a P-gp substrate. Monitor serum digoxin and reduce dose by 30% before initiating eliglustat.

XTANDI can interfere with certain digoxin immunoassays, resulting in falsely elevated digoxin plasma concentration results. Laboratory should use appropriate assay method.

Concomitant use may result in elevated serum digoxin levels.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Esomeprazole magnesium may interfere with digoxin bioavailability. Patients should be monitored for digoxin toxicity.

Esomeprazole magnesium may interfere with digoxin bioavailability. Patients may need monitoring for digoxin toxicity.

Esomeprazole increases digoxin bioavailability by approximately 10% (up to 30% in some subjects), potentially increasing digoxin exposure and toxicity risk.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Monitor digoxin levels during ezetimibe and simvastatin initiation.

Limited experience; concomitant use during TASCENSO ODT initiation may be associated with severe bradycardia or heart block.

Flecainide acetate increases plasma digoxin levels by 13% to 19% at six hours postdose during multiple oral doses.

Concomitant use did not significantly affect pharmacokinetics or pharmacodynamics in clinical studies. Monitor patients for potential hemorrhage risk if co-administration is necessary.

Fostamatinib may increase concentrations of digoxin (P-glycoprotein substrate). Monitor for toxicities that may require dosage reduction.

Gepotidacin increases digoxin exposures. Monitor digoxin serum concentration as appropriate with concomitant administration.

May result in increased serum digoxin levels; close monitoring of serum levels necessary.

Concomitant use may result in increased serum digoxin levels; serum digoxin levels should be closely monitored.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Supraventricular arrhythmias may mask cardiotoxicity from excessive digoxin levels. Use caution in patients with elevated plasma digoxin levels.

Plasma levels of calcium, potassium and magnesium must be carefully monitored in patients using cardiac glycosides like digoxin due to dialysis effects on electrolyte concentrations.

P-glycoprotein substrate. Istradefylline increases digoxin Cmax by 33% and AUC by 21%. Monitor for increased adverse reactions.

Negative chronotrope that increases risk of bradycardia with ivabradine. Monitor heart rate.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Potential for increased exposure of digoxin. Monitor digoxin concentrations and dose adjustment may be needed to maintain therapeutic levels.

Lenacapavir increases digoxin concentration. Use with caution and monitor digoxin therapeutic concentration.

Lenalidomide increases digoxin Cmax and AUC by 14%. Periodically monitor digoxin plasma levels during concomitant administration.

Levalbuterol may decrease serum digoxin levels by 16-22%. Careful evaluation of digoxin levels is prudent in patients receiving both drugs chronically.

Levalbuterol may decrease serum digoxin levels by 16-22%. Monitor digoxin levels in patients receiving chronic therapy.

May decrease serum digoxin levels by 16-22%. Carefully evaluate serum digoxin levels in patients receiving both drugs chronically.

May decrease serum digoxin levels by 16-22%. Consider monitoring digoxin levels in patients receiving concurrent therapy.

May impair digoxin excretion by declining GFR or tubular secretion. Monitor renal function and digoxin levels.

P-gp substrate with increased concentration when coadministered with LIVTENCITY. Monitor serum digoxin concentrations and the dose may need to be reduced.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Cationic drug eliminated by renal tubular secretion with potential for interaction with metformin by competing for common renal tubular transport systems.

Methylene blue inhibits CYP3A4/5 metabolism. Digoxin has narrow therapeutic index; clinical relevance unknown but concurrent use requires caution.

Metoclopramide may diminish absorption of digoxin from the stomach.

Metoclopramide may diminish absorption of digoxin from the stomach.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

CONTRAVE may decrease plasma digoxin levels. Monitor digoxin levels during concurrent use.

Increases digoxin serum concentration by 27% and AUC by 15%. Requires monitoring and dose adjustment.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Oral neomycin inhibits gastrointestinal absorption of digoxin; serum levels should be monitored.

Nicardipine may increase digoxin concentration. Serum digoxin levels should be evaluated after initiating concomitant therapy with nicardipine.

Nicardipine hydrochloride usually does not alter plasma levels of digoxin; however, serum digoxin levels should be evaluated after initiating concomitant therapy.

Administration with nifedipine increased digoxin levels by average 45% in some studies. Monitor digoxin levels when initiating, adjusting, or discontinuing nifedipine to avoid over- or under-digitalization.

Although may be useful in combination with digoxin, additive effects on AV node conduction can result in advanced or complete heart block.

Decline in GFR or tubular secretion may impair digoxin excretion. Individualize digoxin dosage and monitor.

Octreotide decreases digoxin peak exposure; careful assessment of clinical response is needed due to narrow therapeutic ratio.

Increases digoxin concentrations; magnitude unclear. Requires monitoring and dose adjustment.

Omeprazole and sodium bicarbonate increases bioavailability of digoxin by approximately 10%. Monitor patients for potential digoxin toxicity.

Paroxetine decreases plasma concentrations of digoxin. Digoxin dosage may need increase with concentration monitoring.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

SUFLAVE can reduce absorption of digoxin. Administer at least 2 hours before and not less than 6 hours after SUFLAVE to avoid chelation with magnesium.

Monitor digoxin plasma concentrations during posaconazole coadministration due to potential increase.

Monitor digoxin plasma concentrations during posaconazole coadministration.

May be falsely detected as digoxin in standard radioimmunoassays, causing falsely elevated digoxin levels up to 0.5 ng/mL.

Primaquine may inhibit P-gp, potentially increasing digoxin concentrations. Monitor for adverse reactions.

Increases digoxin serum concentration by 24% and AUC by 24%. Requires monitoring and dose adjustment.

Digoxin AUC increased 34-38%. Reduce digoxin dose by 15-30% and monitor serum concentrations.

Increases digoxin serum concentration by 29% and AUC by 19%. Requires monitoring and dose adjustment.

Potential for increased exposure of digoxin; monitor digoxin concentrations and adjust dose if needed.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Increased plasma concentrations may result in potential adverse reactions.

Increases digoxin serum concentration by 27% and AUC by 49%. Requires monitoring and dose adjustment.

SEYSARA may increase digoxin concentrations as a P-glycoprotein substrate. Monitor for toxicities and adjust dosage if needed.

Monitor digoxin levels during simvastatin initiation.

Reduced absorption of digoxin due to chelation with magnesium. Administer at least 2 hours before and not less than 6 hours after CLENPIQ.

Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution can reduce absorption of digoxin via chelation with magnesium. Administer digoxin at least 2 hours before and not less than 6 hours after this product.

Reduced absorption due to chelation with magnesium. Administer at least 2 hours before and not less than 6 hours after SUTAB.

Administer at least 2 hours before and not less than 6 hours after SUPREP to avoid chelation with magnesium and reduced absorption.

Increased digoxin exposure when coadministered with sotagliflozin. Monitor digoxin levels appropriately during concomitant use.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Sucralfate reduces the bioavailability of digoxin. Dosing digoxin 2 hours before sucralfate eliminates the interaction.

Reduced absorption of digoxin reported when administered concomitantly with sulfasalazine.

Suvorexant slightly increases digoxin levels by inhibiting intestinal P-gp; monitor digoxin concentrations.

Digoxin may cause additive bradycardic effect with thalidomide and should be used with caution. Safety of long-term concomitant use not evaluated.

Administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.

Ticagrelor inhibits P-glycoprotein transporter. Monitor digoxin levels with initiation or change in ticagrelor therapy.

P-gp substrate; P-gp inhibition occurs after first dose of APTIVUS/ritonavir followed by induction over time; may alter oral bioavailability and plasma concentrations.

Increases digoxin serum concentration by 30% and AUC by 20%. Requires monitoring and dose adjustment.

Monitor for increased digoxin serum levels when used concomitantly with trazodone.

Increases digoxin serum concentration by 22-28%. Requires monitoring and dose adjustment.

CAPRELSA increases plasma concentrations of digoxin. Use caution and closely monitor for toxicities.

GEMTESA (vibegron) increases digoxin maximal concentrations and systemic exposure. Serum digoxin concentrations should be monitored before initiating and during therapy, and adjusted accordingly.

Concomitant use of vilazodone increased digoxin concentrations. Monitor due to narrow therapeutic index of digoxin.

Exposure may increase with renal impairment when used concomitantly with zoledronic acid. Monitor serum creatinine in patients at risk.

Interaction studies in humans have shown no effect on digoxin blood levels.

Combined administration of citalopram and digoxin did not significantly affect pharmacokinetics of either drug.

No significant effect on pharmacokinetics of either drug in controlled studies.

Darifenacin did not have clinically relevant effect on digoxin pharmacokinetics; routine therapeutic monitoring should be continued.

Darifenacin did not have clinically relevant effect on digoxin pharmacokinetics. Routine monitoring should continue.

In vitro data indicate doxazosin has no effect on protein binding of digoxin.

Dutasteride does not alter the steady-state pharmacokinetics of digoxin when administered concomitantly.

Used concomitantly with enalapril maleate without evidence of clinically significant adverse interactions.

Combined administration did not significantly affect pharmacokinetics of either drug; no significant interaction expected.

Combined administration did not significantly affect pharmacokinetics of either citalopram or digoxin in clinical studies.

Pharmacokinetics of digoxin in heart failure patients were not significantly altered when given concomitantly with felodipine.

No clinically meaningful interaction identified in testing.

Irbesartan administration for 7 days had no effect on the pharmacokinetics of digoxin.

Concomitant administration does not affect renal, nonrenal, or total body clearance of digoxin.

Levetiracetam did not influence digoxin pharmacokinetics or pharmacodynamics; digoxin did not influence levetiracetam pharmacokinetics.

Lisinopril has been used concomitantly with digoxin without evidence of clinically significant adverse interactions or meaningful pharmacokinetic interactions.

Losartan did not affect the pharmacokinetics of oral or intravenous digoxin.

Losartan did not affect the pharmacokinetics of oral or intravenous digoxin. No significant interaction found.

ECG intervals were not affected by concurrent mexiletine and digoxin; mexiletine does not alter serum digoxin levels.

No dose adjustment needed when co-administered with montelukast sodium.

No dose adjustment needed when co-administered with montelukast sodium.

No significant drug interactions reported when co-administered with olmesartan medoxomil in healthy volunteers.

Controlled pharmacokinetic study showed no effect on plasma digoxin concentrations, though effect of digoxin on perindopril/perindoprilat not excluded.

Concurrent administration did not affect digoxin bioavailability parameters.

Prazosin has been administered without adverse drug interaction with digoxin in limited clinical experience.

Administered without adverse drug interaction in limited clinical experience.

Risperidone does not show clinically relevant effect on digoxin pharmacokinetics. Dose adjustment for digoxin not recommended.

Coadministration did not alter the steady-state pharmacokinetics of digoxin.

Concomitant administration did not significantly alter the steady state pharmacokinetics of digoxin. No dose adjustment required.

Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin.

Trandolapril did not affect plasma concentration of oral digoxin; no clinically significant interaction observed.

Concomitant use did not affect the pharmacokinetics of either drug.

No clinically significant pharmacokinetic interactions were observed when coadministered with valsartan.

Interaction not reported in azithromycin clinical trials but observed with other macrolides. Careful monitoring is advised.

Drug interactions have been observed with other macrolide products. Careful monitoring of patients is advised until further data are developed.

P-gp substrate. In vitro studies suggest pretomanid may inhibit P-gp, potentially increasing digoxin exposure. Clinical impact unknown; monitor for adverse reactions.

Clinical studies of interactions with digoxin have not been conducted; potential interaction unknown.